Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 46493 

Dated: August 1, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E6–13191 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Adoptive T-Cell Transfer After 

Lymphodepletion Promotes Tumor 

Regression 

Description of Technology: Available 

for licensing is a method of adoptive 

cell transfer (ACT) immunotherapy. 

Since its first description, ACT is now 

being developed for the supportive 

treatment of a variety of infectious 

diseases and cancer. 

Current ACT methods to treat cancer 

are based on the ex vivo selection of 

lymphocytes with high avidity for 

recognition of tumor antigens, and their 

activation and numerical expansion 

before re-infusion to the autologous 

tumor-bearing host. The current 

invention improves ACT by including a 

pre-treatment regimen to ensure 

permissive conditions in the host for in 

vivo proliferation of the transferred 

cells. Specifically, the immune system 

is suppressed by pre-treatment with 

lymphodepleting chemotherapy. Two 

separate clinical trials have 

demonstrated that using this approach, 

ACT can induce lasting tumor 

shrinkage. 

Lymphodepleting chemotherapy 

followed by ACT resulted in tumor 

shrinkage of at least 50 percent in 6 out 

of 13 treated patients suffering from 

refractory melanoma. Several patients 

remained cancer free for more than a 

year after treatment. The usefulness of 

combined ACT and lymphodepleting 

therapy for cancer treatment was 

confirmed when this study was 

extended to include 35 melanoma 

patients. Eighteen of the 35 patients 

(51%) responded to the treatment, 

including 3 patients who experienced 

ongoing complete disappearance of 

cancer and 15 patients had tumor 

shrinkage of at least 50 percent with a 

mean duration of almost a year after 

treatment. In a recent clinical trial that 

is not yet published, using a modified 

protocol to treat 23 patients, a similar 

response rate (56%) was seen. 

This approach to ACT offers a 

potentially significant improvement in 

the treatment of many types of cancer. 

In addition, this method might be 

applicable in treating other diseases 

such as AIDS, immunodeficiency, or 

other autoimmunity for which immune 

effector cells can impact the clinical 

outcome. 

Inventors: Mark E. Dudley, Steven A. 

Rosenberg, John R. Wunderlich (NCI) 

Publications: 

1 . Dudley ME, et al. ‘‘Adoptive cell 

transfer therapy following nonmyeloablative but lymphodepleting 

chemotherapy for the treatment of 

patients with refractory metastatic 

melanoma.’’ J Clin Oncol. 2005 Apr 

1;23(10):2346–2357. 

2 . Dudley ME, et al. ‘‘Cancer 

regression and autoimmunity in patients 

after clonal repopulation with antitumor 

lymphocytes.’’ Science. 2002 Oct 

25;298(5594):850–854. 

Patent Status: U.S. Provisional 

Application No. 60/408,681 filed 06 Sep 

2002 (HHS Reference No. E–275–2002/ 

0–US–01) PCT Application No. PCT/ 

US03/27873 filed 05 Sep 2003, which 

published as WO 2004/021995 on 18 

Mar 2004 (HHS Reference No. E–275–

2002/1–PCT–01) 

U.S. Patent Application No. 10/ 

526,697 filed 05 May 2005 (HHS 

Reference No. E–275–2002/1–US–02) 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Michelle A. 

Booden, Ph.D.; 301/451–7337; 

boodenm@mail.nih.gov 

Collaborative Research Opportunity: 

The NCI Surgery Branch is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize ACT therapy. Please 

contact Steven A. Rosenberg, M.D., 

Ph.D. at 301–496–4164 for more 

information. 

Dated: August 3, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E6–13193 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute, Special Emphasis Panel, 

Cardiovascular Cell Therapy Research 

Network Review. 

Date: August 14–15, 2006. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: David A. Wilson, PhD, 

Scientific Review Administrator, Review 

Branch, Division of Extramural Affairs, 

National Heart, Lung, and Blood Institute, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 7204, MSC 7924, Bethesda, MD 

20892, 301/435–0929, 

wilsond@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Heart, Lung, 

and Blood Institute, Special Emphasis Panel, 

Minority Undergraduation Biomedical 

Education. 

Date: August 16, 2006. 

Time: 9 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 


jlentini on PROD1PC65 with NOTICES
46494 Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Roy L. White, PhD, 

Scientific Review Administrator, Division of 

Extramural Affairs, Review Branch, National 

Heart, Lung, and Blood Institute, NIH, 6701 

Rockledge Drive, Rm. 7202, Bethesda, MD 

20892–7924, 301/435–0310, 

whiterl@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Heart, Lung, 

and Blood Institute, Special Emphasis Panel, 

Atherosclerosis in a Swine Model. 

Date: August 23, 2006. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Katherine M. Malinda, 

PhD, Scientific Review Administrator, 

Review Branch, Division of Extramural 

Affairs, National Heart, Lung, and Blood 

Institute, 6701 Rockledge Drive, Room 7198, 

Bethesda, MD 20892, (301) 435–0297, 

malindak@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Heart, Lung, 

and Blood Institute, Special Emphasis Panel, 

Shared Resource Grant Application Review. 

Date: August 25, 2006. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Sheiley S. Sehnert, PhD, 

Scientific Review Administrator, Review 

Branch, NIH/NHLBI, 6701 Rockledge Drive, 

Room 7206, Bethesda, MD 20892–7924, 301/ 

435–0303, ssehnert@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Lung Biology Program Project. 

Date: August 31, 2006. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge Center Two, 6701 Rockledge 

Drive, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Keith A. Mintzer, PhD, 

Scientific Review Administrator, Division of 

Extramural Affairs, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6701 Rockledge Drive, Room 7186, NSC 

7924, Bethesda, MD 20892, 301–435–0280, 

mintzerk@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: August 7, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–6875 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Committee for 

Biomedical Imaging and Bioengineering. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed blow in 

advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended. 

The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council or Biomedical Imaging and 

Bioengineering. 

Date: September 15, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: Grant applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Anthony Demsey, PhD, 

Director, Office of Extramural Policy, 

National Institute of Biomedical Imaging and 

Bioengineering, 6701 Democracy Blvd, Room 

241, Bethesda, MD 20892. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nibib1.nih.gov/about/NACBIB/ 

NACBIB.htm, where an agenda and any 

additional information for the meeting 

will be posted when available. 

Dated: August 7, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–6876 Filed 8–11–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel. 

Date: August 31, 2006. 

Time: 10 a.m. to 1 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: NIEHS/National Institutes of Health, 

Building 4401, East Campus, 79 T.W. 

Alexander Drive, 122, Research Triangle 

Park, NC 27709. 

Contact Person: Michelle Victalino, 

Scientific Review Branch, Division of 

Extramural Research and Training, Nat’l 

Institute of Environmental Health Sciences, 

P.O. Box 12233, MD EC–30, Research 

Triangle Park, NC 27709, 919/541–3035, 

victoalinom@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 


jlentini on PROD1PC65 with NOTICES